OakChart

Inspire Medical Systems Inc

INSPHealthcare·Medical Devices·USA·Small·NYSE·Nov 11 • 11:37 AM ET

61.62-0.69 (-1.11%)
2026-11-11 17:37 CET
Market cap
1,804.88 USD m
Revenue, TTM
880.94 USD m
Net income, TTM
100.72 USD m
Free cash flow, TTM
97.89 USD m
EPS diluted, TTM
3.43
P/E
17.99
Compare

Price

INSP against its 20, 50 and 200-day averages
2050200beatmiss
40.0050.0060.0070.0080.002.6M5.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INSPclose 61.6220-day 68.1150-day 69.01200-day 57.6361.6252w low

58.1% under the 52-week high of 147.03 on 10 Dec 2025. 52-week low 38.91 on 3 Jun 2026. Last 15 sessions, 21.7% high to low

Profile

INSP
52-week range, 21% of the way up
38.91147.03

Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The firm offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. It operates through the United States and All Other Countries geographical segments. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

IndexRUT
Employees1333
IPOMay 03, 2018
Beta0.66
ATR, 14d3.08
Rel volume0.55
Short float15.17%
Insider own5.72%
Inst own121.86%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.78B
Enterprise Value1.49B
Income100.72M
Sales880.94M
Book/sh28.57
Cash/sh11.32
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees1333
IPOMay 03, 2018

Ratios

P/E17.99
Forward P/E40.43
PEG-
P/S2.03
P/B2.16
P/C5.44
P/FCF18.23
EV/EBITDA43.15
EV/Sales1.69
Quick Ratio4.61
Current Ratio6.45
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)3.43
EPS next Y1.52
EPS next Q0.92
EPS this Y-46.25%
EPS next Y17.18%
EPS next 5Y-5.45%
EPS past 3/5Y- -
Sales past 3/5Y30.77% 51.21%
EPS Y/Y TTM131.98%
Sales Y/Y TTM-0.19%
EPS Q/Q-351.33%
Sales Q/Q-7.93%
EarningsNov 02 AMC
EPS/Sales Surpr.60.92% 1.17%

Ownership

Insider Own5.72%
Insider Trans-0.30%
Inst Own121.86%
Inst Trans-6.06%
ROA11.44%
ROE13.49%
ROIC11.77%
Gross Margin86.19%
Oper. Margin1.79%
Profit Margin11.43%
SMA20-9.53%
SMA50-10.71%
SMA2006.92%
Trades-

Technical

Shs Outstand28.94M
Shs Float27.31M
Short Float15.17%
Short Ratio5.50
Short Interest4.14M
52W High147.03 -58.09%
52W Low38.91 58.37%
Volatility4.92% 4.22%
ATR (14)3.08
RSI (14)36.70
Beta0.66
Rel Volume0.55
Avg Volume753.46K
Volume150,097

Performance

Perf Week-7.49%
Perf Month-10.51%
Perf Quarter5.88%
Perf Half Y46.99%
Perf YTD-33.19%
Perf Year-31.98%
Perf 3Y-50.98%
Perf 5Y-77.52%
Perf 10Y-
Recom2.89
Target Price69.62
Prev Close62.31
Price61.62
Change %-1.11%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 07, 2026InitiatedBBarclaysUnderweight$65+5.5%
Aug 04, 2026UpgradeOOppenheimerPerform → Outperform$85+37.9%
Jul 28, 2026ResumedUUBSSell$39-36.7%
Jun 23, 2026DowngradeEEvercore ISIOutperform → In-line$40-35.1%
May 22, 2026DowngradeBBofA SecuritiesNeutral → Underperform$39-36.7%
May 05, 2026DowngradePPiper SandlerOverweight → Neutral$55-10.7%
May 05, 2026DowngradeBBofA SecuritiesBuy → Neutral$53-14.0%
Feb 13, 2026DowngradeWWolfe ResearchOutperform → Peer Perform
Feb 12, 2026DowngradeWWells FargoOverweight → Equal Weight$70+13.6%
Feb 12, 2026DowngradeRRobert W. BairdOutperform → Neutral$74+20.1%

Peers

Mkt cap
TickerCompanyMkt cap
NYXHNyxoah SA90.30M
LIVNLivaNova PLC4.98B
RMDResmed Inc32.97B
MDTMedtronic Plc129.23B
NPCENeuroPace Inc438.00M
AHCOAdaptHealth Corp1.06B
BSXBoston Scientific Corp66.29B
VVOSVivos Therapeutics Inc2.98M
SIBNSI-BONE Inc1.12B
LLYLilly(Eli) & Co1337.84B

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
JOHN RONDONIOfficerAug 24 '26Proposed Sale62.36643,991Aug 24 04:29 PM
Kelly Jason PSee RemarksAug 07 '26Sale59.5596357,34718,985Aug 11 07:13 PM
JASON P KELLYOfficerAug 07 '26Proposed Sale59.5596357,342Aug 07 04:08 PM
Rondoni JohnSee RemarksMay 15 '26Sale43.282,641114,30227,165May 19 04:05 PM
JOHN RONDONIOfficerMay 15 '26Proposed Sale43.282,641114,304May 15 04:17 PM
Rondoni JohnSee RemarksMay 14 '26Sale43.0170030,10729,806May 15 04:05 PM
JOHN RONDONIOfficerMay 14 '26Proposed Sale43.0170030,106May 14 04:34 PM
mcCormick ShawnDirectorMay 08 '26Sale45.3169631,53627,712May 11 04:05 PM
SHAWN T MCCORMICKDirectorMay 08 '26Proposed Sale45.5769631,717May 08 04:22 PM
Rondoni JohnSee RemarksJan 09 '26Sale100.0010910,90013,797Jan 12 04:05 PM
JOHN RONDONIOfficerJan 09 '26Proposed Sale95.0010910,355Jan 09 04:32 PM
mcCormick ShawnDirectorDec 02 '25Sale139.001,200166,80024,846Dec 04 04:05 PM
SHAWN T MCCORMICKDirectorDec 02 '25Proposed Sale126.341,200151,608Dec 02 04:27 PM
mcCormick ShawnDirectorNov 28 '25Sale127.482,000254,96026,046Dec 01 05:56 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 206
  • Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference (GlobeNewswire) -7.90% +7.61%
  • Inspire: Q3 Earnings Snapshot (Associated Press)
  • Inspire Medical Tops Consensus But Misses The Whisper As Its Reimbursement Story Turns Toward Recovery (Earnings Whispers)
  • Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results (GlobeNewswire)
  • Inspire Medical's Third Quarter Tests Whether The Coding Shock Has Finally Bottomed (Earnings Whispers)
  • Loading…
  • Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer (Business Wire)
  • Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
  • Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 (GlobeNewswire)
  • Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT Codes by the AMA Editorial Panel (GlobeNewswire)
  • Is ResMed A Better Way Than Stryker To Own Medical Device Growth? (Trefis)
  • Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
  • Which Medtech Giant Would Buy Inspire Medical Systems? (Trefis)
  • Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly) +22.83%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-020.1400.087-0.840206.7204.3116
2026Q22026-08-030.140-0.2360.011200.58194.7216
2026Q12026-05-040.100-0.275-0.394204.58200.0414
2025Q42026-02-111.6500.7424.652269.08265.6916
2025Q32025-11-030.380-0.1890.336224.5220.418
2025Q22025-08-040.4500.202-0.122217.09214.2918
2025Q12025-05-050.100-0.2480.099201.32195.1817
2024Q42025-02-101.1500.7321.145239.72236.7517
2024Q32024-11-040.6000.0620.604203.19197.5916
2024Q22024-08-060.320-0.1400.322195.89189.0817
2024Q12024-05-07-0.340-0.651-0.338164.01161.4117
2023Q42024-02-060.490-0.0540.488192.51186.7515
2023Q32023-11-07-0.290-0.580-0.291153.3154.4913
2023Q22023-08-01-0.410--0.409151.09--
2023Q12023-05-02-0.530-0.660-0.530127.9120.0712
2022Q42023-02-070.100-0.6070.104137.9131.079

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.400-1.418-1.39782.0578.96
2020FY-2.190-2.402-2.194115.38111.3
2021FY-1.540-1.894-1.542233.39229.61
2022FY-1.600-2.291-1.599407.86401.02
2023FY-0.720-1.294-0.722624.8619.5
2024FY1.7501.3351.752802.8799.62
2025FY2.4201.6834.890911.98908.54
2026FY-1.301--855.37
2027FY-1.524--877.73
2028FY-2.046--932.13
2029FY-2.614--998.56
2030FY-2.903--1,079

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-041625243.66238.22251.6
2026Q4S2026-11-031625243.59237.11251.6
2026Q4S2026-11-021600244.35230.46251.6
2026Q4S2026-10-181600244.35230.46251.6
2026Q4S2026-10-121661244.35230.46251.6
2026Q4S2026-09-181661244.35230.5251.6
2026Q4S2026-08-301661244.38230.5252
2026Q4S2026-08-041662244.38230.5252
2026Q4S2026-07-271601241.75223250.1
2026Q4S2026-07-191501241.72223250.1
2026Q4S2026-06-3015013241.72223250.1
2026Q4S2026-06-2916014242.07223250.1
2026Q4S2026-06-1615014241.81223250.1
2026Q4S2026-06-1215014242.16223250.1

Estimate history

EPS, annual-0.824-1.497-1.397-2.194-1.542-1.599-0.7221.7524.8873.4258
Period201720182019202020212022202320242025TTM
EPS, quarterly0.6041.1450.099-0.1220.3364.652-0.3940.011-0.843
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual28.56750.59382.05115.381233.394407.856624.799802.804911.981880.94
Period201720182019202020212022202320242025TTM
Sales, quarterly203.191239.718201.317217.086224.501269.077204.583200.581206.695
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual21.25323.40224.10727.06927.41629.00829.5629.7428.57928.942
Period201720182019202020212022202320242025MRQ
Shares, quarterly29.96329.7429.46729.56929.05328.57928.80228.90728.942
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue880.94911.98802.80624.80407.86233.39115.3882.0550.59
Cost of Goods Sold Incl. D&A121.70133.22122.9996.5866.1133.2817.6213.6410.06
Gross Profit759.24778.76679.82528.22341.74200.1297.7668.4140.54
Selling, General and Administrative Excl. Other743.47727.80643.74568.49389.33239.97153.97103.3060.91
Research and Development97.64103.17114.13116.5468.6437.3526.0912.847.39
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income15.7650.9536.08-40.27-47.59-39.85-56.21-34.90-20.38
Interest Expense0.120.140.020.001.682.132.122.123.30
Unusual Expense0.004.050.000.000.000.000.000.00-0.59
Net Income Before Taxes30.8265.7058.45-19.91-44.27-41.97-57.09-33.20-21.83
Income Taxes-69.89-79.724.941.250.610.070.120.040.00
Consolidated Net Income100.72145.4253.51-21.15-44.88-42.04-57.20-33.24-21.83
Net Income From Continuing Operations100.72145.4253.51-21.15-44.88-42.04-57.20-33.24-21.83
Net Income100.72145.4253.51-21.15-44.88-42.04-57.20-33.24-21.83
EPS (Recurring)3.484.981.75-0.72-1.60-1.54-2.19-1.40-1.53
EPS (Basic, Before Extraordinaries)3.484.951.80-0.72-1.60-1.54-2.19-1.40-1.50
EPS (Diluted)3.434.891.75-0.72-1.60-1.54-2.19-1.40-1.50
EBITDA34.4364.9142.63-37.42-44.69-37.86-54.40-33.50-19.98
Non-Operating Income (Expense)15.1818.9322.3920.365.000.011.243.811.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense92.31102.9091.6565.1541.0619.119.364.521.22
Price To Earnings Ratio18.1918.19172.24------
Price To Sales Ratio2.283.017.059.5417.3426.8742.5021.5312.18
Gross Margin86.1985.3984.6884.5483.7985.7484.7383.3780.12
Operating Margin1.795.594.49-6.45-11.67-17.07-48.72-42.53-40.28
Net Margin11.4315.956.67-3.39-11.00-18.01-49.58-40.52-43.14
Shares Outstanding28.9428.5829.7429.5629.0127.4227.0724.1123.40
Market Capitalization1,804.881,804.885,555.266,006.117,277.426,294.005,066.241,785.72967.19

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue206.69200.58204.58269.08224.50217.09201.32239.72
Cost of Goods Sold Incl. D&A28.8429.1227.6736.0731.7734.6730.7135.99
Gross Profit177.86171.46176.91233.01192.73182.41170.61203.73
Selling, General and Administrative Excl. Other206.57171.97178.03186.90183.08185.73172.09171.85
Research and Development22.1824.7025.8324.9424.2126.2127.8030.34
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-28.72-0.51-1.1246.119.64-3.32-1.4931.88
Interest Expense0.000.000.000.120.010.000.000.02
Unusual Expense0.000.000.000.000.004.050.000.00
Net Income Before Taxes-25.013.122.4050.3213.55-2.334.1636.64
Income Taxes-0.622.8013.69-85.773.621.261.171.41
Consolidated Net Income-24.390.31-11.29136.099.93-3.592.9935.22
Net Income From Continuing Operations-24.390.31-11.29136.099.93-3.592.9935.22
Net Income-24.390.31-11.29136.099.93-3.592.9935.22
EPS (Recurring)-0.840.01-0.394.660.34-0.030.101.15
EPS (Basic, Before Extraordinaries)-0.840.01-0.394.700.34-0.120.101.18
EPS (Diluted)-0.840.01-0.394.650.34-0.120.101.15
EBITDA-23.584.083.9949.9313.320.101.5634.36
Non-Operating Income (Expense)3.713.633.524.333.925.035.644.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense21.2624.6724.2422.1329.4732.9624.5323.02
Price To Earnings Ratio18.199.9810.3963.2642.9859.8091.88172.24
Price To Sales Ratio2.281.441.622.952.494.455.757.10
Gross Margin86.0585.4886.4786.5985.8584.0384.7584.99
Operating Margin-13.89-0.26-0.5517.144.30-1.53-0.7413.30
Net Margin-11.800.16-5.5250.584.42-1.651.4914.69
Shares Outstanding28.9428.9128.8028.5829.0529.5729.4729.74
Market Capitalization1,804.881,285.361,474.642,679.872,194.413,827.424,740.125,555.26

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments308.27445.55460.38451.41214.47234.36149.47188.2116.14
Short Term Receivables119.6993.0789.8861.2334.1825.0613.136.673.86
Inventories145.2980.1233.8811.8917.238.485.832.673.67
Other Current Assets10.4012.079.605.502.661.972.211.730.43
Total Current Assets583.65630.81593.74530.03268.54269.87170.64199.2824.10
Net Property, Plant & Equipment121.4095.2462.6524.1316.4111.123.960.800.99
Total Investments and Advances96.3371.009.140.009.940.006.280.000.00
Intangible Assets-------0.000.00
Deferred Tax Assets99.84--------
Other Assets17.2611.3411.2810.710.200.200.380.000.00
Total Assets918.49808.38676.81564.88295.08281.19181.25200.0825.09
Short Term Debt Incl. Current Port. of LT Debt2.161.750.001.349.500.000.830.000.00
Accounts Payable36.5638.6938.8426.8511.667.214.463.433.00
Income Tax Payable2.451.61-------
Other Current Liabilities54.8846.4539.2733.0020.1413.5211.577.734.15
Total Current Liabilities96.0688.5078.1161.1941.3120.7316.8611.157.15
Long Term Debt30.0030.0424.857.5424.5930.6324.5224.9316.46
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities11.18--------
Other Liabilities0.100.151.350.150.130.090.040.000.16
Total Liabilities137.33118.69104.3068.8766.0451.4441.4236.0823.76
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00119.11
Common Equity781.16689.70572.51496.01229.05229.75139.84164.00-117.78
Total Shareholders Equity781.16689.70572.51496.01229.05229.75139.84164.001.33
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity781.16689.70572.51496.01229.05229.75139.84164.001.33
Total Liabilities & Stockholders Equity918.49808.38676.81564.88295.08281.19181.25200.0825.09
Book Value Per Share27.3323.1919.3717.108.358.495.807.01-5.54
Tangible Book Value Per Share27.3323.1919.3717.108.358.495.807.01-5.54
Full-Time Employees1,3331,2461,011755485317239165121
Price to Book Ratio2.187.9710.9915.4427.5422.1612.796.039.13
Return on Assets16.847.21-3.41-10.44-14.59-24.74-17.44-19.39-91.66
Return on Equity19.778.48-3.96-12.38-18.33-30.96-21.88-26.41-
Return on Invested Capital17.937.43-3.54-8.91-16.58-21.97-20.23-11.55-98.45
Quick Ratio4.566.227.178.476.0812.619.7817.632.86
Current Ratio6.087.137.608.666.5013.0210.1217.863.37

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income100.72145.4253.51-21.15-44.88-42.04-57.20-33.24-21.83
Depreciation18.6713.966.552.852.901.991.811.400.39
Other Funds (Non Cash)138.25133.73107.9083.7451.7426.7913.225.041.88
Funds from Operations183.43204.36167.9665.439.76-13.26-42.17-26.80-19.55
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-48.46-87.38-37.71-40.781.81-6.86-10.88-6.570.86
Cash from Operating Activities134.97116.98130.2524.6511.57-20.12-53.05-33.38-18.69
Capital Expenditures-37.08-38.50-39.12-23.63-9.10-4.67-2.46-2.74-0.25
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments34.5159.95-74.00-271.19-10.5033.8189.08-40.82-83.14
Purchase of Investments-241.14-250.44-418.60-281.44-10.50-9.99-52.72-178.07-115.48
Sale Or Maturity of Investments275.66310.38344.6110.250.0043.80141.80137.2532.34
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.5721.45-113.12-294.82-19.6029.1486.63-43.56-83.39
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-44.60-160.41-47.2331.11259.6214.95134.062.50182.38
Repurchase of Common Pref Stock-50.01-175.02-75.000.000.000.000.000.000.00
Sale of Common Pref Stock5.4214.6127.7731.11259.6214.95134.062.50182.38
Proceedsfrom Stock Options2.190.000.000.00243.800.00124.650.00181.82
Issuance or Reduction of Debt, Net0.000.000.000.00-24.500.000.000.008.00
Change in Long Term Debt0.000.000.000.00-24.500.000.000.008.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.008.00
Reduction of Long Term Debt0.000.000.000.00-24.500.000.000.000.00
Net Financing Active Other Cash Flow-9.72-23.04-5.17-17.16-0.040.000.000.000.00
Other Financing Activities Uses-9.72-23.04-5.17-17.16-0.040.000.000.000.00
Cash from Financing Activities-54.31-183.45-52.3913.95235.0814.95134.062.50190.38
Exchange Rate Effect-0.13-0.31-0.120.160.07-0.020.010.01-
Net Change in Cash77.96-45.34-35.39-256.06227.1223.95167.66-74.4388.33
Free Cash Flow97.8978.4891.121.022.47-24.79-55.50-36.12-18.94
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow20.5034.9762.145,821.232,859.16----
Deferred Taxes & Investment Tax Credit--88.750.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments327.97320.68283.83308.27322.59300.89
Short Term Receivables104.71103.34105.09119.69107.99137.69
Inventories178.96170.45166.24145.29141.78121.63
Other Current Assets15.9914.2011.6610.4014.1312.97
Total Current Assets627.62608.67566.82583.65586.49573.19
Net Property, Plant & Equipment107.76126.93123.76121.40115.58109.80
Total Investments and Advances125.1294.48115.8896.3388.35109.83
Deferred Tax Assets74.2077.5887.6799.84--
Other Assets18.3318.3317.2517.2617.309.38
Total Assets953.03925.99911.38918.49807.72802.19
Short Term Debt Incl. Current Port. of LT Debt0.000.000.002.162.272.15
Accounts Payable38.0727.1041.8536.5659.2453.16
Income Tax Payable---2.451.001.10
Other Current Liabilities59.2744.0847.5754.8848.3336.95
Total Current Liabilities97.3471.1889.4296.06110.8493.36
Long Term Debt28.6129.0929.5530.0030.3030.91
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---11.18--
Other Liabilities0.140.140.070.100.110.11
Total Liabilities126.08100.41119.04137.33141.26124.38
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity826.95825.58792.34781.16666.46677.81
Total Shareholders Equity826.95825.58792.34781.16666.46677.81
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity826.95825.58792.34781.16666.46677.81
Total Liabilities & Stockholders Equity953.03925.99911.38918.49807.72802.19
Book Value Per Share28.5728.5627.5127.3322.9422.92
Tangible Book Value Per Share28.5728.5627.5127.3322.9422.92
Full-Time Employees---1,333--
Price to Book Ratio2.181.621.894.023.246.01
Return on Assets11.4415.6315.9716.845.566.94
Return on Equity13.4917.9618.3719.776.548.07
Return on Invested Capital-2.850.04-1.3716.781.43-0.51
Quick Ratio4.616.164.484.564.014.84
Current Ratio6.458.556.346.085.296.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-24.390.31-11.29136.099.93-3.59
Depreciation5.144.605.113.823.683.41
Other Funds (Non Cash)47.9631.0031.1328.1629.4845.42
Funds from Operations32.0946.0625.9679.3243.0945.24
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital14.34-22.83-13.11-26.8525.44-42.56
Cash from Operating Activities46.4323.2312.8552.4768.532.68
Capital Expenditures-7.54-9.16-9.73-10.66-10.44-9.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments24.5912.71-1.52-1.26-1.2155.56
Purchase of Investments-95.95-24.93-57.31-62.94-76.25-93.92
Sale Or Maturity of Investments120.5437.6455.7961.6875.05149.48
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities17.053.55-11.25-11.92-11.6446.56
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.312.600.11-47.61-49.655.43
Repurchase of Common Pref Stock0.000.000.00-50.01-50.000.00
Sale of Common Pref Stock0.312.600.112.400.355.43
Proceedsfrom Stock Options0.002.190.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.75-0.69-7.59-0.69-1.43-1.73
Other Financing Activities Uses-0.75-0.69-7.59-0.69-1.43-1.73
Cash from Financing Activities-0.441.91-7.48-48.31-51.083.70
Exchange Rate Effect0.000.140.00-0.280.120.10
Net Change in Cash63.0428.83-5.88-8.035.9253.05
Free Cash Flow38.8814.073.1241.8158.09-6.31
Price to Free Cash Flow20.5011.0315.3134.3422.2345.04

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 802.80M 2025: 911.98M
Non-US2024: 31.76M 2025: 39.90M
United States2024: 771.04M 2025: 872.09M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.17%4.1M27.3M773.44K
2026-10-1516.48%4.5M27.3M801.50K
2026-09-3015.39%4.2M27.3M805.14K
2026-09-1514.41%3.9M27.3M855.63K
2026-08-3113.41%3.7M27.3M881.59K
2026-08-1416.04%4.4M27.3M1.01M
2026-07-3114.38%3.9M27.3M1.15M
2026-07-1515.99%4.3M27.2M1.16M
2026-06-3017.28%4.7M27.2M1.17M
2026-06-1513.21%3.6M27.2M1.12M
2026-05-2913.60%3.7M27.2M1.12M
2026-05-1513.55%3.7M27.2M1.17M
2026-04-3011.83%3.2M26.9M1.14M
2026-04-1510.71%2.9M27.0M1.27M
2026-03-3112.01%3.2M26.7M1.25M
2026-03-1313.39%3.6M26.7M1.47M
2026-02-2714.09%3.8M26.7M1.59M
2026-02-1314.79%3.9M26.7M1.65M
2026-01-3013.94%3.9M27.8M1.64M
2026-01-1510.63%3.0M27.8M1.54M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call22.5037.6041.200.005.8070.000.000.965-0.1800.007
call25.0035.0038.700.005.2730.000.000.962-0.1780.008
call30.0030.4033.500.004.2270.000.000.953-0.1730.010
call35.0025.7028.5013.503.4881.000.000.942-0.1670.011
call40.0020.7023.7030.902.94925.000.000.928-0.1590.013
call45.0015.8018.7026.202.3601060.000.909-0.1490.016
call50.0010.5013.7019.251.8169.000.000.881-0.1350.019
call55.006.108.9017.551.35614.000.000.744-0.2280.031
call60.001.854.305.240.9096.000.000.596-0.2120.037
call65.000.103.401.701.24442.000.000.422-0.2520.038
call70.000.000.650.670.7954100.000.168-0.1080.024
call75.000.002.250.411.0582070.000.135-0.1240.021
call80.000.002.151.511.2864220.000.116-0.1350.019
call85.000.002.150.051.4891710.000.104-0.1450.017
call90.000.002.151.001.67429.000.000.095-0.1520.016
call95.000.002.151.601.8436.000.000.088-0.1590.015
call1000.002.151.822.0056.000.000.083-0.1640.015
call1050.002.151.252.1455.000.000.079-0.1690.014
call1100.002.151.252.2832.000.000.075-0.1740.014
put22.500.002.150.104.33362.000.00-0.035-0.1770.007
put25.000.002.150.153.92571.000.00-0.038-0.1750.008
put30.000.002.150.053.22212.000.00-0.047-0.1700.010
put35.000.002.150.102.63322.000.00-0.058-0.1630.011
put40.000.002.153.552.1162.000.00-0.072-0.1550.013
put45.000.002.150.051.6522280.00-0.090-0.1430.016
put50.000.000.750.101.2201160.00-0.119-0.1290.019
put55.000.002.150.431.29711.000.00-0.256-0.2220.031
put60.000.053.301.251.06119.000.00-0.404-0.2050.037
put65.002.705.902.200.99839.000.00-0.578-0.2450.038
put70.006.709.106.890.79842.000.00-0.833-0.1000.024
put75.0011.4014.5011.901.07429.000.00-0.865-0.1160.021
put80.0016.4019.6019.021.5345.000.00-0.884-0.1270.019
put85.0021.4024.8013.901.8440.000.00-0.896-0.1350.017
put90.0026.4029.800.002.0520.000.00-0.905-0.1420.016
put95.0031.4034.900.002.2860.000.00-0.912-0.1480.015
put10036.4039.700.002.3700.000.00-0.917-0.1530.015
put10541.4044.600.002.4800.000.00-0.921-0.1580.014
put11046.4049.700.002.6820.000.00-0.925-0.1620.014

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09SCHEDULE 13G/ASEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13GSEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-044Statement of changes in beneficial ownership of securities2025-07-31SEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-273Initial statement of beneficial ownership of securities2026-07-20SEC
2026-07-248-KCurrent report2026-07-20SEC
2026-07-228-KCurrent report2026-07-16SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-02SCHEDULE 13GSEC
2026-06-268-KCurrent report2026-06-26SEC
2026-06-01SDSpecialized Disclosure ReportSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080057.35K1
2026-070000
2026-060000
2026-0500175.95K3
2026-040000
2026-030000
2026-020000
2026-010010.90K1
2025-1200166.80K1
2025-1100254.96K1

Institutional holders

Manager% owned
BlackRock, Inc.16.44%
WELLINGTON MANAGEMENT GROUP LLP8.27%
VANGUARD PORTFOLIO MANAGEMENT LLC7.25%
Soleus Capital Management, L.P.6.70%
AQR CAPITAL MANAGEMENT LLC6.44%
UBS Group AG6.40%
D. E. Shaw & Co., Inc.5.10%
NOMURA HOLDINGS INC4.75%
DEERFIELD MANAGEMENT COMPANY, L.P.4.50%
VANGUARD CAPITAL MANAGEMENT LLC4.41%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND7.27%
iShares Core S&P Small-Cap ETF5.48%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.17%
iShares Russell 2000 ETF2.60%
VANGUARD SMALL-CAP INDEX FUND2.29%
Artisan International Small-Mid Fund1.58%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.32%
Fidelity Small Cap Index Fund1.10%
VANGUARD EXTENDED MARKET INDEX FUND1.05%
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF0.83%

OakChart. INSP. Cached 15 minutes.